Non-squamous non-small-cell lung carcinoma (NSCLC) tumours are tested for driver mutations and rearrangements, typically EGFR, ALK, ROS1, MET, and BRAF. In many centres, it is also common to screen for less frequent but potentially targetable mutations, including RET, ERBB2/HER2, and NTRK fusions .
In time, novel immune checkpoint inhibitors (ICIs) will treat growing numbers of driver cell mutations in squamous and non-squamous tumours. Combinations of ICIs alone and with chemotherapy hold promise for prolonging PFS and OS in patients with high PD-L1 expressing tumours. Growing knowledge of the biology of NSCLC is rapidly reshaping treatment advanced disease.
Patient-reported health-related quality of life (HRQoL) outcomes from the CheckMate 227 study  suggest rapid and sustained improvements in patients treated with nivolumab + ipilimumab vs chemotherapy.
The phase 3, randomised CheckMate 227 trial enrolled patients with advanced NSCLC and a high tumou...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Angiogenic and stromal biomarkers in malignant mesothelioma Next Article
Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer »
Table of Contents: WCLC 2018
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.